PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization Market
Tel Aviv – April 10, 2025 — PainReform Ltd. (Nasdaq: PRFX) PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven software […]
PainReform Provides Year-End Business Update
Tel Aviv, Israel – April 7, 2025 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of the DeepSolar activities, today provided a business update for the year ended December 31, 2024. Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, […]
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Tel Aviv, Israel – March 5, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing […]
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
DeepSolar brings new customer base in creation, including major utility-scalesolar operators and independent power producers, whilebreaking into the residential solar market The Company remains committed to advancing its drug deliverytechnologies while broadening its growth potential Tel Aviv, Israel – February 18, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical […]
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
Tel Aviv, Israel – December 27, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from […]
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
Tel Aviv, Israel – November 20, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research (“Lotus”), for the Phase 3 clinical trial evaluating PRF-110 in […]
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market Tel Aviv, Israel – November 7, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification […]
PainReform Ltd. Confirms Sutures Compatibilityin Human Clinical Trials for PRF-110
Positive Compatibility Results Reinforce Safety and Efficacyof PRF-110 in Post-Surgical Pain Management Tel Aviv, Israel – September 11, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its […]
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the […]
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures
PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive EdgeOver Leading Pain Management Products Tel Aviv, Israel – August 21, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful determination of the optimal delivery […]
